We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


NanoBio and the University of Michigan to Receive $9.3M NIH Grant

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NanoBio and the University of Michigan to Receive $9.3M NIH Grant"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
NanoBio Corporation has announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

NanoBio will receive a subcontract of approximately $4.1 million over the research period to support efforts aimed at developing nanoemulsion-based mucosal vaccine adjuvants for a wide variety of antigens.

“NanoBio’s nanoemulsion-based vaccine adjuvant platform has consistently demonstrated the ability to elicit robust systemic, cellular and mucosal immunity, based on studies we’ve conducted in numerous diseases using various antigen types,” commented David Peralta, NanoBio’s CFO and COO. “This award will fund extensive additional research that will allow NanoBio and the University of Michigan to further advance our adjuvant platform for vaccines.”

NanoBio announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. The Phase 1 study is currently ongoing.

The underlying technology is NanoBio’s NanoStat™ platform, which employs a nanoemulsion that is created through a proprietary manufacturing process. The nanoemulsion is capable of permeating the nasal mucosa, where it can load vaccine antigen into immune-presenting cells. These cells then carry the antigen to areas of the body that initiate an immune response, including the lymph nodes, thymus and spleen.

“Our unique approach to inducing immunity leverages nasal immune elements to produce a level of protective immunity not seen with currently available vaccines,” added Mr. Peralta. “This funding will enable NanoBio to make tremendous advances in terms of mucosal vaccination, which could provide significant advantages with respect to disease protection worldwide.”